Now Reading:
Unleashing the Power of AI: HistoIndex Redefines NASH Clinical Trials with Stain-Free Tissue Imaging at EASL Congress 2023
Full Article 50 second read

Unleashing the Power of AI: HistoIndex Redefines NASH Clinical Trials with Stain-Free Tissue Imaging at EASL Congress 2023

By Daniella Parra

HistoIndex will present advancements in AI-powered stain-free tissue imaging for NASH clinical trials at the EASL Congress 2023.

“HistoIndex’s participation in the EASL Congress and the acceptance of our research partners’ 14 abstract submissions exemplify our unwavering commitment in advancing the field of NASH digital pathology,” said Dr. Gideon Ho, Ph.D., CEO at HistoIndex.

“We have seen from the multitude of published data that SHG/TPE imaging with AI analyses can help augment pathologist reads and if we can fully quantify the key features of NASH activity and fibrosis using innovative stain-free AI-based digital pathology; and understand their correlation with outcomes, we will be better equipped to design more effective clinical trials that facilitate regulatory approvals in drug development,” said Dr. Stephen Harrison, Chairman, and Founder at Pinnacle Clinical Research, Chairman and Co-Founder at Summit Clinical Research.

Contact:

Healthcare Edge

Editor@Executives-edge.com

Leave a Reply

Your email address will not be published. Required fields are marked *

Input your search keywords and press Enter.